Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

Midazolam is a rapid-acting benzodiazepine, with a short half-life (approximately 1.9 hours) and is primarily metabolised by CYP3A.

Omeprazole is a selective proton pump inhibitor substrate used to reduce gastric acid secretion. Omeprazole is primarily metabolised by CYP2C19.

Midazolam and omeprazole are both used as probe drugs in clinical pharmacology studies to evaluate clinical CYP3A and CYP2C19 drug interactions, respectively. Furthermore the EMA and the FDA guidance on drug interactions recommend the use of these drugs for such evaluations.

The aim of this study is to assess the effect of PQ912 on the PK of midazolam and omeprazole. In vitro studies have demonstrated that PQ912 inhibits several CYP enzymes, including CYP3A4 and CYP2C19 and at the expected exposure levels in patients, has the potential to inhibit these enzymes in-vivo. This study is therefore planned to investigate the potential changes in the PK of midazolam and omeprazole due to the effect of PQ912 at steady-state. In clinical practice it is likely that co-administration of PQ912 with other drugs that are metabolised via the CYP3A and/or CYP2C19 enzymes will occur. This study will provide important information for the requirement of dose adjustments or contraindications in these circumstances.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Probiodrug AG; Vivoryon Therapeutics N.V.
• Collaborator: Covance
• Treatments: Midazolam; Omeprazole; Proton Pump Inhibitors

Criteria

Inclusion Criteria:

• males

• of any ethnic origin

• between 18 and 55 years of age

• body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive

• body weight between 50 kg and 100 kg inclusive

• must be in good health,

• will have given written informed consent and to abide by the study restrictions

Exclusion Criteria:

• history of any clinically significant disease or disorder which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, may influence the results, or may limit the subject's ability to participate in the study

• history or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs

• active participation in a clinical study or participation in a clinical study investigating a new chemical entity within 3 months or 5 half-lives (whichever is longer prior to first dose)

• clinically significant illness within 4 weeks of the start of the dose administration